FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108463> ?p ?o ?g. }

• W4310108463 endingPage "7044" @default.
• W4310108463 startingPage "7043" @default.
• W4310108463 abstract "Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults, with more than 90% of newly diagnosed cases occurring in patients more than 64 years of age. It is to be noted that multiple studies reported improved survival over the past 4 decades which is attributed to advancement in treatment and understanding of the disease. However, to better examine the burden of CLL in the United States (US) we investigated the incidence and incidence-based mortality rates in the US over the past 4 decades using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: SEER-8 registry, 8.3% of the US population, was used to study CLL/SLL cases from 1978-2019. Incidence-based (IBR) and incidence-based mortality (IBMR) rates were calculated by sex, age, and ethnicity/race. Patients were divided into four categories according to age of diagnosis, wherein <55 (young-onset CLL), 55-64, 65-74 and >75 years of age. Annual percent change was then calculated using joinpoint regression software. The best model with the least number of joinpoints was then selected. Results: Over the study period, CLL IBR increased by 0.75% (p=0.202). The overall IBR steadily increased from 1978 until 2013 before declining at a rate of -2.05%/year (p=0.031). Males’ IBR plateaued until 1998 followed by an increase of 2.80%/year (p<0.001) until 2011 only to then decline by -1.72%/year (p=0.028). Similarly, females’ IBR had insignificant fluctuations from 1978-2002 followed by an increase of 2.44%/year (p<0.001) until 2011 and an insignificant decline from 2011-2019 (APC=-1.07%/year, p=0.222). Among patients with young-onset CLL, IBR increased by 0.57%/year (p=0.034) up to 2008 and by 11.89%/year (p=0.521) from 2008-2011, followed by a decline of -1.39%/year (p=0.465). Likewise, patients >75 years of age's IBR declined by 0.52%/year (p=0.028) till 1998, increased by 4.01%/year (p<0.001) to 2010, and then declined by 2.02%/year (p=0.011). After years of increasing rates among Whites', IBR declined among Whites beginning in 2013 (APC=-2.12%/year; p=0.037). In contrast, Blacks’ rates increased by 0.96%/year (p<0.001) throughout the study period. (Figure) Over the study period, CLL IBMR was 2.10%/year (p<0.001). The overall CLL IBMR steadily increased from 1978 till 2012 and stabilized at -0.38%/year (p=0.457) until 2019. Males’ IBMR increased by 26.61%/year (p<0.001) during 1978-1980, then increased at a slower rate of 2.97%/year (p<0.001) and 0.46%/year (p<0.001) between 1980-1989 and 1989-2019, respectively. Similarly, females’ rates increased by 11.91%/year (p<0.001) between 1978-1984, and by 0.52%/year (p<0.001) between 1984-2019. Young-onset CLL rates increased by 46.69%/year (p=0.236) during 1978-1980, then declined by -1.85%/year (p<0.001) from 1980 to 2019. In contrast, >75 years old's IBMR increased by 14.00%/year (p<0.001) between 1978-1982 followed by a steady increase of 1.30%/year between 1982-2019. Whites’ IBMR increased from 1978 till 2012, then plateaued at a rate of -0.10%/year (p=0.857) until 2019. Blacks’ IBMR increased by 7.65%/year (p<0.001) between 1978-1991 followed by an insignificant decline of -4.87%/year (p=0.063) from 1991-2000 and an increase of 1.40%/year (p=0.056) between 2000-2019. (Figure) Conclusion: Our findings showed a decline in CLL incidences since 2013, with plateauing of mortality rates since 2012 which is in line with recent advances in the management of CLL. Additionally, our study demonstrated improved mortality rates among the black population and those <75 years of age. Further studies will be needed to better characterize the effect of newer targeted therapies on IBMRs. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310108463 created "2022-11-30" @default.
• W4310108463 creator A5025628249 @default.
• W4310108463 creator A5028756836 @default.
• W4310108463 creator A5030849191 @default.
• W4310108463 creator A5063701745 @default.
• W4310108463 creator A5085665709 @default.
• W4310108463 creator A5089279339 @default.
• W4310108463 date "2022-11-15" @default.
• W4310108463 modified "2023-09-27" @default.
• W4310108463 title "Trends of Chronic Lymphocytic Leukemia Incidence and Mortality in the United States: A Population-Based Study over the Last Four Decades" @default.
• W4310108463 doi "https://doi.org/10.1182/blood-2022-169374" @default.
• W4310108463 hasPublicationYear "2022" @default.
• W4310108463 type Work @default.
• W4310108463 citedByCount "0" @default.
• W4310108463 crossrefType "journal-article" @default.
• W4310108463 hasAuthorship W4310108463A5025628249 @default.
• W4310108463 hasAuthorship W4310108463A5028756836 @default.
• W4310108463 hasAuthorship W4310108463A5030849191 @default.
• W4310108463 hasAuthorship W4310108463A5063701745 @default.
• W4310108463 hasAuthorship W4310108463A5085665709 @default.
• W4310108463 hasAuthorship W4310108463A5089279339 @default.
• W4310108463 hasConcept C107130276 @default.
• W4310108463 hasConcept C120665830 @default.
• W4310108463 hasConcept C121332964 @default.
• W4310108463 hasConcept C126322002 @default.
• W4310108463 hasConcept C144024400 @default.
• W4310108463 hasConcept C149923435 @default.
• W4310108463 hasConcept C187212893 @default.
• W4310108463 hasConcept C2777938653 @default.
• W4310108463 hasConcept C2778461978 @default.
• W4310108463 hasConcept C2778527826 @default.
• W4310108463 hasConcept C2780558122 @default.
• W4310108463 hasConcept C2908647359 @default.
• W4310108463 hasConcept C61511704 @default.
• W4310108463 hasConcept C71924100 @default.
• W4310108463 hasConcept C99454951 @default.
• W4310108463 hasConceptScore W4310108463C107130276 @default.
• W4310108463 hasConceptScore W4310108463C120665830 @default.
• W4310108463 hasConceptScore W4310108463C121332964 @default.
• W4310108463 hasConceptScore W4310108463C126322002 @default.
• W4310108463 hasConceptScore W4310108463C144024400 @default.
• W4310108463 hasConceptScore W4310108463C149923435 @default.
• W4310108463 hasConceptScore W4310108463C187212893 @default.
• W4310108463 hasConceptScore W4310108463C2777938653 @default.
• W4310108463 hasConceptScore W4310108463C2778461978 @default.
• W4310108463 hasConceptScore W4310108463C2778527826 @default.
• W4310108463 hasConceptScore W4310108463C2780558122 @default.
• W4310108463 hasConceptScore W4310108463C2908647359 @default.
• W4310108463 hasConceptScore W4310108463C61511704 @default.
• W4310108463 hasConceptScore W4310108463C71924100 @default.
• W4310108463 hasConceptScore W4310108463C99454951 @default.
• W4310108463 hasIssue "Supplement 1" @default.
• W4310108463 hasLocation W43101084631 @default.
• W4310108463 hasOpenAccess W4310108463 @default.
• W4310108463 hasPrimaryLocation W43101084631 @default.
• W4310108463 hasRelatedWork W1494634337 @default.
• W4310108463 hasRelatedWork W2003396225 @default.
• W4310108463 hasRelatedWork W2019643847 @default.
• W4310108463 hasRelatedWork W2022537897 @default.
• W4310108463 hasRelatedWork W2060022074 @default.
• W4310108463 hasRelatedWork W2088591622 @default.
• W4310108463 hasRelatedWork W2558898034 @default.
• W4310108463 hasRelatedWork W2806305939 @default.
• W4310108463 hasRelatedWork W33073900 @default.
• W4310108463 hasRelatedWork W4289867877 @default.
• W4310108463 hasVolume "140" @default.
• W4310108463 isParatext "false" @default.
• W4310108463 isRetracted "false" @default.
• W4310108463 workType "article" @default.